# Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

> **NCT01240629** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 43 (actual)

## Conditions studied

- Prostate Cancer
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **OTHER:** laboratory biomarker analysis
- **OTHER:** questionnaire administration
- **DRUG:** doxorubicin-GnRH agonist conjugate AEZS-108

## Key facts

- **NCT ID:** NCT01240629
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-02
- **Primary completion:** 2017-02-02
- **Final completion:** 2017-02-02
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2017-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01240629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01240629, "Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01240629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*